Avacta Group PLC (AIM:AVCT) has announced that shipment of its new rapid COVID-19 test has started.
The AffiDX SARS-CoV-2 antigen lateral flow test is a high performance, 20-minute antigen test using nasal swabbing that is CE marked for professional use in the UK and EU.
The assay has been shown by independent clinical evaluation to be 100% sensitive for patient samples with a high viral load, 98% sensitive across a much wider range of viral loads and with 99% specificity.
It also detects all the major variants of the virus including the delta variant.
The AIM-listed firm has recently appointed Calibre Scientific, a global distributor of diagnostic and life science products, as the first distributor for the test in the UK and EU.
It’s discussing with distributors and potential clients in other countries too.
"Manufacturing scale up continues to progress well and we remain focused on the challenge of being able to supply the clear demand in the market,” commented chief executive Dr Alastair Smith.
"We continue to see significant levels of commercial interest from around the world and are progressing a number of opportunities in a range of sectors.”